BioNTech and Pfizer’s three dose Covid-19 vaccine appears to be 80% effective against the omicron variant for children, according to data released from the company on Monday. Reportedly, the immune systems of children ranging from 6 months to 5 years responded to the vaccine shot strongly.
Children’s side effects ranged from mild to moderate.
The companies plan to complete their application that requests the Food and Drug Administration to authorize the vaccine for emergency usage, according to BioNTech’s CEO Ugur Sahin.
Pfizer CEO Albert Bourla released a statement regarding his own hopes for the vaccine based on the results of the data.
“These topline safety, immunogenicity and efficacy data are encouraging,” said Pfizer CEO Albert Bourla. “We look forward to soon completing our submissions to regulators globally with the hope of making this vaccine available to younger children as quickly as possible, subject to regulatory authorization.”
The findings of the highly effective Pfizer vaccine shot for young children was a result of the company’s Phase 2/3 clinical trial. According to CNN, the trial included 1,678 children under the age of 5 receiving a third dose during the Omicron predominant variant time period.
Allegedly, the children received 3-microgram shots which is one-tenth of the dosage level chosen for adults. The first two doses were given three weeks apart after the third dose being given at least two months after.
According to the Food and Drug Administration, their outside experts will meet on June 15 to discuss the youngest children’s status regarding the Moderna and Pfizer-BioNTech vaccine.